search
Back to results

Dietary Supplementation With Blueberry in OA

Primary Purpose

Knee Osteoarthritis

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Blueberry powder supplement
Maltodextrin supplementation
Sponsored by
University of Exeter
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Knee Osteoarthritis

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Participants capable of giving informed consent Sex: Male and female Age: > 40 years - Those under 40 are more likely to have an undiagnosed secondary cause of osteoarthritis BMI: > 18 kg/m2 Listed to have a total knee replacement for osteoarthritis Participants are permitted to participate in other ongoing surgical intervention studies, as long as these are not trials of a dietary supplement or a medication. Exclusion Criteria: Those who have received intravenous or oral immunosuppressant medications in past 2 years Those who have had intra-articular steroid injection in 6 months preceding surgery. Some secondary causes of osteoarthritis (mechanistic confounders that are likely to influence tissue inflammation measures: Known congenital joint disorders Other inflammatory arthritis e.g. rheumatoid arthritis Avascular necrosis, infectious arthritis Paget disease Osteopetrosis Osteochondritis dissecans Hemochromatosis Wilson's disease Hemoglobinopathy Ehlers-Danlos syndrome Marfan syndrome Acromegaly Those typically consuming more than eight 80 g portions (or juice equivalent) of blueberries, blackberries, strawberries, raspberries, blackcurrants, pomegranate or cherries per week Those with a known fruit allergy, for which they carry an adrenaline auto-injector or have required anti-histamine, adrenaline, glucocorticoid or beta-agonist treatment. Those who cannot adequately understand verbal explanations or written information given in English

Sites / Locations

  • Royal Devon University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo

Blueberry Supplementation

Arm Description

Outcomes

Primary Outcome Measures

Concentration of TNF-ALPHA gene expression in joint tissue (synovium, infrapatellar adipose tissue and cartilage)
Inflammatory protein

Secondary Outcome Measures

Concentration of broad panel of Inflammatory and pro-cartilage cytokines samples
Using multiplex immunoassay including but not limited to at TNFα, IL-6, IL-10 and IL-1β, MIP1α, Galectin 1, Chemerin, Eotaxin, gp130, MCP-1, IL-7, MIP3α, IL-15, Aggrecan, Resistin, Leptin, MIP1β, MMP-1, MMP-3 and MMP-13
Concentration of broad panel of Inflammatory and pro-cartilage degradative gene and protein expression markers
Using RTqPCR and immunoblotting including but not limited to TNFα, IL-6, IL1β, IL-8, IL-10, IL-18, IL-7, IL-15, MCP1, LEP, ADIPOQ, NAMPT, RETN, TGFB1, MMP1, MMP2, MMP3, MMP9, MMP13, TIMP1, TIMP2, TIMP3, TIMP4, ADAMTS4, ADAMTS5, , ACAN, COL1A1, COL2A1, COL13A1, COL14A1, COL15A1, DKK1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL20, CX3CL1, CCR3, CCR2, LGALS1, RARRES2, and IL6ST
Western Ontario and McMaster Universities Arthritis Index Score
Validated questionnaire (0-96 where a higher score is worse)

Full Information

First Posted
March 1, 2023
Last Updated
September 6, 2023
Sponsor
University of Exeter
Collaborators
U.S. Highbush Blueberry Council, Royal Devon University Healthcare NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT05784545
Brief Title
Dietary Supplementation With Blueberry in OA
Official Title
Highbush Blueberry Supplementation for Osteoarthritis Pain, Intra-articular Inflammation and Post-operative Recovery in Total Knee Replacement Patients
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 22, 2023 (Actual)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
April 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Exeter
Collaborators
U.S. Highbush Blueberry Council, Royal Devon University Healthcare NHS Foundation Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Osteoarthritis is a painful long term joint condition that is associated with poor quality of life. There are no treatments to prevent it. Inflammation is one cause of osteoarthritis. This inflammation is complex. It involves many joint tissues, like cartilage and fat. It also involves many proteins that act as inflammatory 'signals'. Safely targeting these proteins with medications has so far proved ineffective. Physiotherapy and weight loss can help osteoarthritis, but there is a need for other approaches. Blueberries are rich in natural chemicals called polyphenols; these have well-established anti-inflammatory effects. Blueberries and other fruits may improve osteoarthritis symptoms, but the investigators do not know how this improvement happens. It may be that these foods reduce inflammation within the joint tissues. They will investigate this. This will help us to understand 1) how blueberries improve osteoarthritis symptoms and 2) whether dietary supplementation with blueberries could slow down joint damage in osteoarthritis, rather than just improving symptoms. Additionally, high levels of joint inflammation predict poorer recovery from joint replacement surgery. Therefore, blueberry supplementation may hasten this recovery. Fifty eight people scheduled to have a knee replacement for osteoarthritis will receive either six weeks blueberry supplementation or a placebo pre-surgery. Participants will continue the supplementation for six weeks after surgery. First, this study will use tissue samples (cartilage, fat and the joint lining called synovium) obtained during surgery to investigate the effects of pre-operative blueberry supplementation on markers of joint inflammation. Second, this study will assess the ability of dietary supplementation with blueberries to improve the symptoms of osteoarthritis. Finally, this study will investigate the effect of blueberry supplementation on recovery from total knee replacement. Our investigations may provide evidence to support dietary supplementation with blueberries to slow down osteoarthritis progression and to improve recovery from osteoarthritis joint replacement surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
58 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
Blueberry Supplementation
Arm Type
Experimental
Intervention Type
Dietary Supplement
Intervention Name(s)
Blueberry powder supplement
Intervention Description
The intervention in this study is 12 weeks of daily blueberry supplementation which is comprised of freeze-dried powdered whole blueberries i.e., blueberries with water removed.
Intervention Type
Dietary Supplement
Intervention Name(s)
Maltodextrin supplementation
Intervention Description
The intervention in this study is 12 weeks of daily maltodextrin supplement used to mimic the carbohydrate composition of whole blueberries.
Primary Outcome Measure Information:
Title
Concentration of TNF-ALPHA gene expression in joint tissue (synovium, infrapatellar adipose tissue and cartilage)
Description
Inflammatory protein
Time Frame
In knee at time of surgery (when replaced)
Secondary Outcome Measure Information:
Title
Concentration of broad panel of Inflammatory and pro-cartilage cytokines samples
Description
Using multiplex immunoassay including but not limited to at TNFα, IL-6, IL-10 and IL-1β, MIP1α, Galectin 1, Chemerin, Eotaxin, gp130, MCP-1, IL-7, MIP3α, IL-15, Aggrecan, Resistin, Leptin, MIP1β, MMP-1, MMP-3 and MMP-13
Time Frame
Baseline and pre-operatively
Title
Concentration of broad panel of Inflammatory and pro-cartilage degradative gene and protein expression markers
Description
Using RTqPCR and immunoblotting including but not limited to TNFα, IL-6, IL1β, IL-8, IL-10, IL-18, IL-7, IL-15, MCP1, LEP, ADIPOQ, NAMPT, RETN, TGFB1, MMP1, MMP2, MMP3, MMP9, MMP13, TIMP1, TIMP2, TIMP3, TIMP4, ADAMTS4, ADAMTS5, , ACAN, COL1A1, COL2A1, COL13A1, COL14A1, COL15A1, DKK1, CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL20, CX3CL1, CCR3, CCR2, LGALS1, RARRES2, and IL6ST
Time Frame
In knee at time of surgery (when replaced)
Title
Western Ontario and McMaster Universities Arthritis Index Score
Description
Validated questionnaire (0-96 where a higher score is worse)
Time Frame
Baseline, week 3, week 6, post-surgery, weeks 7, 9 and 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants capable of giving informed consent Sex: Male and female Age: > 40 years - Those under 40 are more likely to have an undiagnosed secondary cause of osteoarthritis BMI: > 18 kg/m2 Listed to have a total knee replacement for osteoarthritis Participants are permitted to participate in other ongoing surgical intervention studies, as long as these are not trials of a dietary supplement or a medication. Exclusion Criteria: Those who have received intravenous or oral immunosuppressant medications in past 2 years Those who have had intra-articular steroid injection in 6 months preceding surgery. Some secondary causes of osteoarthritis (mechanistic confounders that are likely to influence tissue inflammation measures: Known congenital joint disorders Other inflammatory arthritis e.g. rheumatoid arthritis Avascular necrosis, infectious arthritis Paget disease Osteopetrosis Osteochondritis dissecans Hemochromatosis Wilson's disease Hemoglobinopathy Ehlers-Danlos syndrome Marfan syndrome Acromegaly Those typically consuming more than eight 80 g portions (or juice equivalent) of blueberries, blackberries, strawberries, raspberries, blackcurrants, pomegranate or cherries per week Those with a known fruit allergy, for which they carry an adrenaline auto-injector or have required anti-histamine, adrenaline, glucocorticoid or beta-agonist treatment. Those who cannot adequately understand verbal explanations or written information given in English
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
MARY OLEARY
Phone
01392 724759
Email
m.oleary@exeter.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
LAUREN STRUSZCZAK
Phone
01392 723546
Email
l.r.struszczak@exeter.ac.uk
Facility Information:
Facility Name
Royal Devon University Hospital
City
Honiton
State/Province
Devon
ZIP/Postal Code
EX14 9AJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
LAUREN STRUSZCZAK
Phone
07894456815
Email
l.r.struszczak@exeter.ac.uk

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Dietary Supplementation With Blueberry in OA

We'll reach out to this number within 24 hrs